NYSE: CRLCharles River Laboratories International Inc Stock
$190.46-3.81 (-1.96%)
Updated Dec 13, 2024
CRL Price
$190.46
Fair Value Price
N/A
Market Cap
$9.74B
52 Week Low
$176.48
52 Week High
$275.00
P/E
23.66x
P/B
2.58x
P/S
2.51x
PEG
1.72x
Dividend Yield
N/A
Revenue
$4.06B
Earnings
$423.78M
Gross Margin
34.8%
Operating Margin
15.91%
Profit Margin
10.2%
Debt to Equity
1.1
Operating Cash Flow
$796M
Beta
1.17
Next Earnings
Feb 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CRL Overview
Charles River Laboratories International, Inc. offers a variety of preclinical and clinical laboratory, gene therapy, and cell therapy services to the Pharmaceutical, Medical Device, and Biotechnology sectors. Charles River was founded in 1947 and is headquartered in Wilmington, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Value
C
Growth
D
Momentum
C
Sentiment
A
Safety
B
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important CRL news, forecast changes, insider trades & much more!
CRL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRL ($190.46) is trading above its intrinsic value of $83.02, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRL is good value based on its earnings relative to its share price (23.66x), compared to the US market average (30.75x)
P/E vs Market Valuation
CRL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CRL due diligence checks available for Premium users.
Valuation
CRL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
23.66x
Industry
19.49x
Market
30.75x
CRL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CRL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CRL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.58x
Industry
4.04x
CRL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRL price to earnings growth (PEG)
For valuing profitable companies with growth potential
CRL is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
CRL's financial health
Profit margin
Revenue
$1.0B
Net Income
$69.7M
Profit Margin
6.8%
CRL's Earnings (EBIT) of $646.00M... subscribe to Premium to read more.
Interest Coverage Financials
CRL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.0B
Liabilities
$4.2B
Debt to equity
1.1
CRL's short-term assets ($1.49B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRL's long-term liabilities ($3.16B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$251.8M
Investing
-$21.3M
Financing
-$207.5M
CRL's operating cash flow ($796.16M)... subscribe to Premium to read more.
Debt Coverage Financials
CRL vs Diagnostic & Research Stocks
Charles River Laboratories International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.